Return to homepagePandemic Pact

An Optimized COVID-19 Diagnostic Test Incorporating Host Responses for Predicting Disease Course and Healthcare Needs

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • start year

    -99

  • Known Financial Commitments (USD)

    $0

  • Funder

    Roche Holding AG (Roche)

  • Principal Investigator

    Jeremy Hirota

  • Research Location

    Canada

  • Lead Research Institution

    McMaster University

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Understanding host immune responses to SARS-CoV-2 infection may yield prognostic indicators useful for optimizing healthcare delivery at the time of initial nasal swab collection for COVID-19 diagnosis. Nasal swabs are collected for COVID-19 clinical diagnosis, presenting a research opportunity to leverage remaining nucleic acids for host transcriptomic profiling and correlating with clinical outcomes. The objective is to correlate host transcriptome profiles from nasal swabs from COVID-19 +ve and -ve cases with clinical outcomes to generate algorithms for predicting patient morbidity/mortality and healthcare utilization, with the aim of optimizing COVID-19 diagnostic testing incorporating host responses.